TrialThe oncologist2021

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.

Alberto Sobrero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.